ReviewAdvances in therapy2022

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Thomas Bieber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.